Cancer News and Research

Latest Cancer News and Research

$16 million federal stimulus funds for cancer research projects

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

6 Oct 2009

More efforts needed to present breast reconstruction options to all patients: Study

Latinas who spoke little English were less likely to undergo reconstruction surgery after a mastectomy for breast cancer, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

FOLOTYN available for commercial sale in the United States

Allos Therapeutics, Inc. today announced that FOLOTYN (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

HealthCare Insight launches new care management program for oncology claims

HealthCare Insight, a division of Verisk Health, Inc., and a provider of clinically validated fraud, abuse, and overpayment prevention solutions for private and public-sector payors, announced today the release of a new care management program for oncology claims.

5 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Bon-Ton Stores to conduct “Shop for a Cure” event to support breast cancer research

The Bon-Ton Stores, Inc. announced today the official kick-off to National Breast Cancer Awareness Month with special promotions to support breast cancer research. On Wednesday, October 7, Bon-Ton will hold a “Shop for a Cure” one-day shopping event. The Company will donate 1% of all purchases made on its proprietary credit card on October 7 to fund breast cancer research.

5 Oct 2009

PrimeraDx receives its fourth patent

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled “Methods and systems for dynamic gene expression profiling”, with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations.

5 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.

5 Oct 2009

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.

5 Oct 2009

Oral Cancer Foundation initiates program to donate VELscope screening systems

The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.

5 Oct 2009

Cancer News and Research

Latest Cancer News and Research

$16 million federal stimulus funds for cancer research projects

More efforts needed to present breast reconstruction options to all patients: Study

YM BioSciences to acquire Cytopia

FOLOTYN available for commercial sale in the United States

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

HealthCare Insight launches new care management program for oncology claims

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Bon-Ton Stores to conduct “Shop for a Cure” event to support breast cancer research

PrimeraDx receives its fourth patent

Preclinical study results of AVL-181 protease inhibitor presented

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Oral Cancer Foundation initiates program to donate VELscope screening systems

Cancer Research - Second Edition eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in